Abstract
OBJECTIVE: To investigate the effects of ranibizumab combined with laser photocoagulation on macular volume and best corrected visual acuity (BCVA) in patients with macular edema secondary to ischemic retinal vein occlusion. METHODS: The clinical data of 90 patients (90 eyes) with macular edema secondary to ischemic retinal vein occlusion treated in our hospital from June 2018 to December 2021 were retrospectively analyzed. Patients were divided into Groups-A, B, and C according to the type of treatment they received. The Group-A was treated with laser photocoagulation, the Group-B was intravitreally injected with ranibizumab, and the Group-C underwent ranibizumab combined with laser photocoagulation. The efficacy, intraocular pressure, BCVA, central macular thickness (CMT) and adverse reactions were compared among the three groups. RESULTS: The total efficacy of the Group-C was higher than that of the Group-A and B, with statistically significant differences (P< 0.05). Three months after treatment, BCVA was higher while CMT was reduced in the Group-C than those in the Group-A and B (P < 0.05). Six months after treatment, BCVA was higher while intraocular pressure was lower and CMT was thinner in the group C compared with the Group-A and B (P< 0.05). CONCLUSIONS: Ranibizumab combined with laser photocoagulation in the treatment of macular edema secondary to ischemic retinal vein occlusion presents significant efficacy, and can effectively reduce macular volume, improve visual acuity and promote the recovery of retinal function.